Low serum testosterone but not obesity predicts high gleason score at biopsy diagnosed as prostate cancer in patients with serum PSA lower than 20 ng/ml

Masaki Shiota, Ario Takeuchi, Masaaki Sugimoto, Takashi Dejima, Eiji Kashiwagi, Keijiro Kiyoshima, Junichi Inokuchi, Katsunori Tatsugami, Akira Yokomizo

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: The impact of testosterone or obesity on the pathological grade of prostate cancer remains controversial. Therefore, in this study, we investigated the relationship of serum testosterone and body mass index (BMI) to Gleason score at biopsy. Patients and Methods: This study included 128 Japanese patients diagnosed with prostate cancer from 2000 through 2012 whose serum testosterone level and BMI were measured before treatment. Associations between clinical parameters, including pre-treatment serum testosterone level and BMI, and Gleason score at biopsy were examined. Results: The median serum testosterone and BMI were 434 ng/dl (interquartile range=362-542 ng/dl) and 23.5 kg/m2 (interquartile range=21.7-25.4 kg/m2), respectively. Gleason score at biopsy was <7, 7 and >7 for 58 patients (45.3%), 52 patients (40.6%) and 18 patients (14.1%), respectively. On univariate analysis, positive finding at digital rectal examination (DRE), high prostate-specific antigen level at diagnosis and low serum testosterone level, but not BMI, were correlated with high Gleason score at biopsy. Multivariate analysis identified positive finding at DRE and low serum testosterone level as significant predictors of a high Gleason score at prostate biopsy. By combining these parameters, the predictive ability of a high Gleason score was improved. Conclusion: This study showed that positive finding at DRE and a low pre-treatment serum testosterone level, but not obesity, may be factors predictive of aggressive prostate cancer, indicating the diagnostic value of serum testosterone, as well as DRE findings, in risk assessment.

Original languageEnglish
Pages (from-to)6137-6145
Number of pages9
JournalAnticancer research
Volume35
Issue number11
Publication statusPublished - Nov 2015

Fingerprint

Neoplasm Grading
Testosterone
Prostatic Neoplasms
Obesity
Biopsy
Digital Rectal Examination
Serum
Body Mass Index
Prostate-Specific Antigen
Prostate
Therapeutics
Multivariate Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Low serum testosterone but not obesity predicts high gleason score at biopsy diagnosed as prostate cancer in patients with serum PSA lower than 20 ng/ml. / Shiota, Masaki; Takeuchi, Ario; Sugimoto, Masaaki; Dejima, Takashi; Kashiwagi, Eiji; Kiyoshima, Keijiro; Inokuchi, Junichi; Tatsugami, Katsunori; Yokomizo, Akira.

In: Anticancer research, Vol. 35, No. 11, 11.2015, p. 6137-6145.

Research output: Contribution to journalArticle

@article{459dde749b4441e3848df3ebdf38dfd4,
title = "Low serum testosterone but not obesity predicts high gleason score at biopsy diagnosed as prostate cancer in patients with serum PSA lower than 20 ng/ml",
abstract = "Background/Aim: The impact of testosterone or obesity on the pathological grade of prostate cancer remains controversial. Therefore, in this study, we investigated the relationship of serum testosterone and body mass index (BMI) to Gleason score at biopsy. Patients and Methods: This study included 128 Japanese patients diagnosed with prostate cancer from 2000 through 2012 whose serum testosterone level and BMI were measured before treatment. Associations between clinical parameters, including pre-treatment serum testosterone level and BMI, and Gleason score at biopsy were examined. Results: The median serum testosterone and BMI were 434 ng/dl (interquartile range=362-542 ng/dl) and 23.5 kg/m2 (interquartile range=21.7-25.4 kg/m2), respectively. Gleason score at biopsy was <7, 7 and >7 for 58 patients (45.3{\%}), 52 patients (40.6{\%}) and 18 patients (14.1{\%}), respectively. On univariate analysis, positive finding at digital rectal examination (DRE), high prostate-specific antigen level at diagnosis and low serum testosterone level, but not BMI, were correlated with high Gleason score at biopsy. Multivariate analysis identified positive finding at DRE and low serum testosterone level as significant predictors of a high Gleason score at prostate biopsy. By combining these parameters, the predictive ability of a high Gleason score was improved. Conclusion: This study showed that positive finding at DRE and a low pre-treatment serum testosterone level, but not obesity, may be factors predictive of aggressive prostate cancer, indicating the diagnostic value of serum testosterone, as well as DRE findings, in risk assessment.",
author = "Masaki Shiota and Ario Takeuchi and Masaaki Sugimoto and Takashi Dejima and Eiji Kashiwagi and Keijiro Kiyoshima and Junichi Inokuchi and Katsunori Tatsugami and Akira Yokomizo",
year = "2015",
month = "11",
language = "English",
volume = "35",
pages = "6137--6145",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "11",

}

TY - JOUR

T1 - Low serum testosterone but not obesity predicts high gleason score at biopsy diagnosed as prostate cancer in patients with serum PSA lower than 20 ng/ml

AU - Shiota, Masaki

AU - Takeuchi, Ario

AU - Sugimoto, Masaaki

AU - Dejima, Takashi

AU - Kashiwagi, Eiji

AU - Kiyoshima, Keijiro

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Yokomizo, Akira

PY - 2015/11

Y1 - 2015/11

N2 - Background/Aim: The impact of testosterone or obesity on the pathological grade of prostate cancer remains controversial. Therefore, in this study, we investigated the relationship of serum testosterone and body mass index (BMI) to Gleason score at biopsy. Patients and Methods: This study included 128 Japanese patients diagnosed with prostate cancer from 2000 through 2012 whose serum testosterone level and BMI were measured before treatment. Associations between clinical parameters, including pre-treatment serum testosterone level and BMI, and Gleason score at biopsy were examined. Results: The median serum testosterone and BMI were 434 ng/dl (interquartile range=362-542 ng/dl) and 23.5 kg/m2 (interquartile range=21.7-25.4 kg/m2), respectively. Gleason score at biopsy was <7, 7 and >7 for 58 patients (45.3%), 52 patients (40.6%) and 18 patients (14.1%), respectively. On univariate analysis, positive finding at digital rectal examination (DRE), high prostate-specific antigen level at diagnosis and low serum testosterone level, but not BMI, were correlated with high Gleason score at biopsy. Multivariate analysis identified positive finding at DRE and low serum testosterone level as significant predictors of a high Gleason score at prostate biopsy. By combining these parameters, the predictive ability of a high Gleason score was improved. Conclusion: This study showed that positive finding at DRE and a low pre-treatment serum testosterone level, but not obesity, may be factors predictive of aggressive prostate cancer, indicating the diagnostic value of serum testosterone, as well as DRE findings, in risk assessment.

AB - Background/Aim: The impact of testosterone or obesity on the pathological grade of prostate cancer remains controversial. Therefore, in this study, we investigated the relationship of serum testosterone and body mass index (BMI) to Gleason score at biopsy. Patients and Methods: This study included 128 Japanese patients diagnosed with prostate cancer from 2000 through 2012 whose serum testosterone level and BMI were measured before treatment. Associations between clinical parameters, including pre-treatment serum testosterone level and BMI, and Gleason score at biopsy were examined. Results: The median serum testosterone and BMI were 434 ng/dl (interquartile range=362-542 ng/dl) and 23.5 kg/m2 (interquartile range=21.7-25.4 kg/m2), respectively. Gleason score at biopsy was <7, 7 and >7 for 58 patients (45.3%), 52 patients (40.6%) and 18 patients (14.1%), respectively. On univariate analysis, positive finding at digital rectal examination (DRE), high prostate-specific antigen level at diagnosis and low serum testosterone level, but not BMI, were correlated with high Gleason score at biopsy. Multivariate analysis identified positive finding at DRE and low serum testosterone level as significant predictors of a high Gleason score at prostate biopsy. By combining these parameters, the predictive ability of a high Gleason score was improved. Conclusion: This study showed that positive finding at DRE and a low pre-treatment serum testosterone level, but not obesity, may be factors predictive of aggressive prostate cancer, indicating the diagnostic value of serum testosterone, as well as DRE findings, in risk assessment.

UR - http://www.scopus.com/inward/record.url?scp=84946074950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946074950&partnerID=8YFLogxK

M3 - Article

C2 - 26504040

AN - SCOPUS:84946074950

VL - 35

SP - 6137

EP - 6145

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 11

ER -